The advanced reproductive age patient is not only a quantity problem — many present with reasonable antral follicle count, retrieve a normal number of oocytes, and still end the cycle with poor maturation and no euploid embryo. The talk reframes that picture as relative LH deficiency: the LH:FSH ratio drifts below 1 in the older patient, and the oocyte loses its competence support.
Relative LH deficiency in patients over 38 affects oocyte quality more reliably than total oocyte yield. A high FSH dose without adequate LH support produces a paradoxical drop in mature-oocyte yield. The two-cell two-gonadotrophin model is most exposed at this age — theca-androgen supply, granulosa-aromatase activity and mitochondrial competence all depend on intact LH signalling.
Measure LH and FSH on day 2-3 and compute the ratio. In patients 38+ with a low LH:FSH ratio, add recombinant LH or HMG to the protocol. Do not chase higher FSH alone in the older patient with a normal antral follicle count and a previous low-maturation cycle — the answer is in LH, not in dose.
LH activity from HMG and recombinant LH is not pharmacokinetically identical; choice depends on patient and protocol. Mitochondrial decline with age sets a ceiling that no protocol fully escapes. Personalisation needs a previous cycle as anchor data.
An 18-oocyte cycle at 40 with a poor maturation rate is no longer surprising. Why advanced reproductive age is not only quantity but quality, what relative LH deficiency does to oocyte competence, and how to read the LH:FSH ratio when planning a stimulation in the over-38 patient.
